Double-blind, placebo-controlled, phase 3 study Untreated advanced or metastatic NSCLC Group A (Cemiplimab + chemotherapy (n=312)) vs. group B (chemotherapy alone (n=154))

10 Jan

Follicular Lymphoma

New Drug: Mosunetuzumab for R/R Follicular Lymphoma

Single-arm, multicenter, phase 2 study Relapsed or refractory to two or more previous lines of treatment Mosunetuzumab q21 days (n=90)

26 Nov

Breast Cancer

New Protocol: Pembrolizumab with Chemotherapy in Triple-Negative Breast Cancer

Phase 3, randomized, double-blind, international trial Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer Pembrolizumab (200 mg every 3 w

20 Sep

Nervous System TumorThyroid Cancer

New Indication: Dabrafenib and Trametinib in bRAV V600E Mutant Anaplastic Thyroid Cancer

Open-label, nonrandomized, phase II basket study Unresectable or metastatic 36 anaplastic thyroid cancer patients Dabrafenib 150 mg x 2 /day plus trametinib 2 mg/day

16 Jul

Acute myeloid leukemia

New Protocol: Venetoclax with 3 + 7 Chemotherapy for AML

Two-stage, single-arm, phase 2 trial Previously untreated de novo acute myeloid leukaemia IV daunorubicin (60 mg/m2 on days 1-3), IV cytarabine (100 mg/m2 on days 1-7), and oral ve

20 Sep

Renal Cell Carcinoma

New Reference: Nivolumab and Cabozantinib for Advanced RCC

Open-label, randomised, phase 3 trial (CheckMate 9ER) Previously untreated advanced or metastatic clear-cell renal cell carcinoma Nivolumab 240 mg/2 weeks plus cabozantinib 40 mg/d

20 May

Melanoma

New Indication: Adjuvant Pembrolizumab for Melanoma

Double-blind, randomised, phase 3 study (KEYNOTE-716) Newly diagnosed, completely resected stage IIB or IIC melanoma Pembrolizumab (n=483) or placebo (n=486)

20 May

Acute myeloid leukemia

New Protocol: Ivosidenib and Azacitidine in IDH1-Mutated AML

Double-blind, randomized, placebo-controlled, phase 3 trial Newly diagnosed IDH1-mutated acute myeloid leukemia Ineligible for intensive induction chemotherapy Oral ivosidenib and

20 May

Prostate Cancer

New Protocol: Abiraterone with DOCEtaxel in CRPC

Open-label, randomised, phase 3 study (PEACE-1) De novo metastatic prostate adenocarcinoma Standard of care (androgen deprivation therapy alone or with intravenous docetaxel 75 mg/

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries